parp7

RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3 nM.

PARP7-IN-16 free base is the freebase form of PARP7-IN-16. As a selective oral inhibitor of PARP-1 2 7, it demonstrates IC50 values of 0.94, 0.87, and 0.21 nM, respectively. This compound is utilized in the research of breast and prostate cancer.

PARP7-IN-24 (compound 44) is a potent inhibitor of PARP7, demonstrating an EC50 of 0.375 nM for pSTAT1 in NCI-H1373 cells. It shows potential for use in cancer research.

PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.

PARP7-IN-12, a potent inhibitor targeting PARP7, exhibits an IC50 of 7.836 nM. This compound is applicable in cancer research.

PARP7-probe-1, a chemiluminescent-labeled and biotinylated probe, selectively binds to the PARP7 active site, facilitating research into PARP7 function [1].

PARP7-IN-16 (compound 36) is a potent, selective, and orally active inhibitor of PARP-1/2/7, with IC50 values of 0.94, 0.87, and 0.21 nM, respectively, and holds potential applications in breast and prostate cancer research [1].

PARP7-IN-15 (Compound 18) is a potent PARP7 inhibitor with an IC50 of 0.56 nM and demonstrates antitumor activity [1].

Parp7-in-18 (Compound 8) is a selective PARP7 inhibitor with an IC50 of 0.11 nM, demonstrating strong anticancer activity and favorable pharmacokinetic properties [1].

XYL-1 is a potent PARP7 inhibitor with an IC50 of 0.6 nM. It has the capability to enhance type I interferon signaling in vitro, positioning it as a potential candidate for the development of cancer immunotherapy drugs.

OUL243 is a potent and selective inhibitor of mono-ADP-ribosyltransferase (ARTs), effectively suppressing PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15.

RBN012759 inhibits PARP14 protein with an IC50 value of 0.003 μM and is more than 300-fold selective over all PARP family members.[2]

OUL232 is a potent single ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 inhibitor for cancer and tumour research.

YCH1899, an orally active PARP inhibitor, demonstrates potent inhibition of PARP1 2 with an IC50 of less than 0.001 nM. It shows marked antiproliferative efficacy against Olaparib-resistant (Capan-1 OP) and Talazoparib-resistant (Capan-1 TP) cells with IC50 values of 0.89 nM and 1.13 nM, respectively. Moreover, YCH1899 possesses favorable pharmacokinetic attributes in rats [1].